These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 22706858)

  • 21. GATA3 immunohistochemistry in urothelial carcinoma of the upper urinary tract as a urothelial marker and a prognosticator.
    Inoue S; Mizushima T; Fujita K; Meliti A; Ide H; Yamaguchi S; Fushimi H; Netto GJ; Nonomura N; Miyamoto H
    Hum Pathol; 2017 Jun; 64():83-90. PubMed ID: 28428106
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The use of placental S100 (S100P), GATA3 and napsin A in the differential diagnosis of primary adenocarcinoma of the bladder and bladder metastasis from adenocarcinoma of the lung.
    Raspollini MR; Comin CE; Crisci A; Chilosi M
    Pathologica; 2010 Feb; 102(1):33-5. PubMed ID: 20731252
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fascin stain as a potential marker of invasiveness in carcinomas of the urinary bladder: a retrospective study with biopsy and cytology correlation.
    McKnight R; Cohen C; Siddiqui MT
    Diagn Cytopathol; 2011 Sep; 39(9):635-40. PubMed ID: 20949550
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Strong androgen receptor expression is not useful in distinguishing GATA3 + metastases.
    Lionti S; La Rocca L; Nunnari CM; Barresi V
    Pathol Res Pract; 2018 Dec; 214(12):2110-2114. PubMed ID: 30293951
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunohistochemical evaluation of novel and traditional markers associated with urothelial differentiation in a spectrum of variants of urothelial carcinoma of the urinary bladder.
    Paner GP; Annaiah C; Gulmann C; Rao P; Ro JY; Hansel DE; Shen SS; Lopez-Beltran A; Aron M; Luthringer DJ; De Peralta-Venturina M; Cho Y; Amin MB
    Hum Pathol; 2014 Jul; 45(7):1473-82. PubMed ID: 24780825
    [TBL] [Abstract][Full Text] [Related]  

  • 26. GATA3 expression in morphologic subtypes of breast carcinoma: a comparison with gross cystic disease fluid protein 15 and mammaglobin.
    Wendroth SM; Mentrikoski MJ; Wick MR
    Ann Diagn Pathol; 2015 Feb; 19(1):6-9. PubMed ID: 25544392
    [TBL] [Abstract][Full Text] [Related]  

  • 27. GATA binding protein 3 is down-regulated in bladder cancer yet strong expression is an independent predictor of poor prognosis in invasive tumor.
    Miyamoto H; Izumi K; Yao JL; Li Y; Yang Q; McMahon LA; Gonzalez-Roibon N; Hicks DG; Tacha D; Netto GJ
    Hum Pathol; 2012 Nov; 43(11):2033-40. PubMed ID: 22607700
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma.
    Bishop JA; Sharma R; Illei PB
    Hum Pathol; 2010 Jan; 41(1):20-5. PubMed ID: 19740516
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of contemporary prostate and urothelial lineage biomarkers in a consecutive cohort of poorly differentiated bladder neck carcinomas.
    Mohanty SK; Smith SC; Chang E; Luthringer DJ; Gown AM; Aron M; Amin MB
    Am J Clin Pathol; 2014 Aug; 142(2):173-83. PubMed ID: 25015857
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Invasive micropapillary carcinoma of the breast metastatic to the urinary bladder and endometrium: diagnostic pitfalls and review of the literature of tumors with micropapillary features.
    Ramalingam P; Middleton LP; Tamboli P; Troncoso P; Silva EG; Ayala AG
    Ann Diagn Pathol; 2003 Apr; 7(2):112-9. PubMed ID: 12715337
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Utility of GATA3 in the Diagnosis of Urothelial Carcinomas With Variant Morphologic Patterns.
    Verduin L; Mentrikoski MJ; Heitz CT; Wick MR
    Appl Immunohistochem Mol Morphol; 2016 Aug; 24(7):509-13. PubMed ID: 26317312
    [TBL] [Abstract][Full Text] [Related]  

  • 32. GATA3 expression loss is linked to stage progression but is unrelated to prognosis in muscle-invasive urothelial carcinoma of the bladder.
    Plage H; Samtleben H; Hofbauer S; Kornienko K; Weinberger S; Bruch PG; Elezkurtaj S; Roßner F; Schallenberg S; Kluth M; Lennartz M; Blessin NC; Marx AH; Fisch M; Rink M; Slojewski M; Kaczmarek K; Ecke T; Hallmann S; Koch S; Adamini N; Minner S; Simon R; Sauter G; Klatte T; Schlomm T; Horst D; Zecha H
    Hum Pathol; 2022 Dec; 130():10-17. PubMed ID: 36152841
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fascin as an identifier of metastatic urothelial carcinoma: A retrospective study of fine-needle aspiration cell blocks and histologic tissue microarrays.
    Vogt AP; Cohen C; Siddiqui MT
    Diagn Cytopathol; 2012 Oct; 40(10):882-6. PubMed ID: 21433004
    [TBL] [Abstract][Full Text] [Related]  

  • 34. GATA-3 immunohistochemistry in the differential diagnosis of adenocarcinoma of the urinary bladder.
    Ellis CL; Chang AG; Cimino-Mathews A; Argani P; Youssef RF; Kapur P; Montgomery EA; Epstein JI
    Am J Surg Pathol; 2013 Nov; 37(11):1756-60. PubMed ID: 24061521
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Utility of ProEx C in the histologic evaluation of the neoplastic and nonneoplastic urothelial lesions.
    Moatamed NA; Vergara-Lluri ME; Lu D; Apple SK; Kerkoutian S; Rao JY
    Hum Pathol; 2013 Nov; 44(11):2509-17. PubMed ID: 24029711
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diagnostic utility of GATA3 immunohistochemical expression in urothelial carcinoma.
    Agarwal H; Babu S; Rana C; Kumar M; Singhai A; Shankhwar SN; Singh V; Sinha RJ
    Indian J Pathol Microbiol; 2019; 62(2):244-250. PubMed ID: 30971548
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Novel Marker GATA3 is Significantly More Sensitive Than Traditional Markers Mammaglobin and GCDFP15 for Identifying Breast Cancer in Surgical and Cytology Specimens of Metastatic and Matched Primary Tumors.
    Sangoi AR; Shrestha B; Yang G; Mego O; Beck AH
    Appl Immunohistochem Mol Morphol; 2016 Apr; 24(4):229-37. PubMed ID: 25906123
    [TBL] [Abstract][Full Text] [Related]  

  • 38. GATA3 expression in clinically useful groups of breast carcinoma: a comparison with GCDFP15 and mammaglobin for identifying paired primary and metastatic tumors.
    Yang Y; Lu S; Zeng W; Xie S; Xiao S
    Ann Diagn Pathol; 2017 Feb; 26():1-5. PubMed ID: 28038704
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Thyroid transcription factor 1 expression in small cell carcinoma of the urinary bladder: an immunohistochemical profile of 44 cases.
    Jones TD; Kernek KM; Yang XJ; Lopez-Beltran A; MacLennan GT; Eble JN; Lin H; Pan CX; Tretiakova M; Baldridge LA; Cheng L
    Hum Pathol; 2005 Jul; 36(7):718-23. PubMed ID: 16084939
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diagnostic utility and sensitivities of GATA3 antibodies in triple-negative breast cancer.
    Krings G; Nystrom M; Mehdi I; Vohra P; Chen YY
    Hum Pathol; 2014 Nov; 45(11):2225-32. PubMed ID: 25150746
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.